Analysis for Biogen
Analysis summary
Biogen (BIIB) currently has a total score of 36 points, placing it in the weak range. The score is made up of Performance (17), Stability (40) and Trend (80). The profile is clearly uneven: Trend stands out while Performance lags.
Performance scores 17 points (very weak). Key strength: 1Y return at 40.9 %. Main drag: 10Y return at -22.2 %. This points to a sharper upswing more recently.
Stability scores 40 points (neutral). Key strength: Sharpe ratio (90d) at 1.64. Weaker metric: max drawdown (1Y) at -52.1 %. Higher Stability points are better and typically reflect calmer swings and smaller drawdowns—but prices can still fall.
Trend scores 80 points (very strong). Key strength: Price is about 30.5 % above SMA200. Even the weakest metric remains solid in absolute terms: 12M momentum at 21.8 %.
Overall, the profile has a clear strength in Trend, while Performance is the main limiter. On a metric level, SMA200 distance stands out, while 10Y return lags.
(Historical evaluation, not investment advice.)
Metrics
Performance
Stability
FAQ
- What investor type does Biogen fit best in FoxScore?
- Biogen fits a trend/momentum-oriented investor type in FoxScore: trend is clearly the strongest sub-score. This can be useful if you follow trends — but pay close attention to stability (drawdowns/volatility) because trend signals can flip quickly.
- How meaningful is the available history for Biogen?
- Biogen currently has about 15 years of price history available. That covers multiple market cycles including crisis phases, making long-term interpretation of returns, drawdowns and trend shifts more reliable.
- What is FoxScore good for — and what is it not for?
- FoxScore is an analysis and comparison tool: it helps you sort assets quickly, compare profiles and spot strengths/weaknesses. It’s not a substitute for your own research or fundamental analysis, and it’s not a buy/sell recommendation.